Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Cleveland Clinic · Bayer (United States) · +6 more institutions
Abstract
PURPOSE: Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported. PATIENTS AND METHODS: Nine hundred three previously treated patients were randomly assigned to receive sorafenib versus placebo. On demonstration of progression-free survival (PFS) benefit with sorafenib, patients assigned to placebo were offered sorafenib. Overall survival (OS) was determined at two planned interim analyses and one final analysis, with a secondary OS analysis conducted by censoring placebo patients who crossed over to sorafenib. The…
Citation impact
- FWCI
- 85.82
- Percentile
- 100%
- References
- 15
Authors
19- BEBernard EscudierCorresponding
Cleveland Clinic, Bayer (United States), Texas Oncology, Institut Gustave Roussy, University of Chicago, Hôpital Européen Georges-Pompidou, Centrum Onkologii, Ludwig-Maximilians-Universität München
- TETim Eisen
Cleveland Clinic, Bayer (United States), Texas Oncology, Institut Gustave Roussy, University of Chicago, Hôpital Européen Georges-Pompidou, Centrum Onkologii, Ludwig-Maximilians-Universität München
- WMWalter M. Stadler
Cleveland Clinic, Bayer (United States), Texas Oncology, Institut Gustave Roussy, University of Chicago, Hôpital Européen Georges-Pompidou, Centrum Onkologii, Ludwig-Maximilians-Universität München
- CSCezary Szczylik
Cleveland Clinic, Bayer (United States), Texas Oncology, Institut Gustave Roussy, University of Chicago, Hôpital Européen Georges-Pompidou, Centrum Onkologii, Ludwig-Maximilians-Universität München
- SOStéphane Oudard
Cleveland Clinic, Bayer (United States), Texas Oncology, Institut Gustave Roussy, University of Chicago, Hôpital Européen Georges-Pompidou, Centrum Onkologii, Ludwig-Maximilians-Universität München
Topics & keywords
- Sorafenib
- Medicine
- Internal medicine
- Renal cell carcinoma
- Hazard ratio
- Oncology
- Placebo
- Interim analysis
- Good health and well-being